The presence of increasing host chimerism or persistent mixed chimerism (MC) after hematopoietic stem cell transplantation for leukemia in children is a predictor of relapse. To reduce the risk of relapse, we prospectively studied post-transplantation chimerism-based immunotherapy (IT) using fast withdrawal of immunosuppression (FWI) and donor lymphocyte infusions (DLI) in children with early post-transplantation MC. Forty-three children with hematologic malignancies at 2 institutions were enrolled prospectively in this study from 2009 until 2012 and were followed for a mean of 42 (SD, 10) months. Twelve patients (28%) were assigned to the observation arm based on the presence of graft-versus-host disease (GVHD) or full donor chimerism (FDC), and 5 (12%) sustained early events and could not undergo intervention. Twenty-six (60%) patients with MC were assigned to IT with FWI, which started at a median of 49 days (range, 35 to 85 days) after transplantation. Fourteen patients proceeded to DLI after FWI. Toxicities of treatment included GVHD, which developed in 19% of patients undergoing intervention, with 1 of 26 (4%) dying from GVHD and 1 (4%) still requiring therapy for chronic GVHD 21 months after DLI. Patients with MC undergoing IT had similar 2-year event-free survival (EFS) (73%; 95% confidence interval (CI), 55% to 91%) compared with patients who achieved FDC spontaneously (83%; 95% CI, 62% to 100%); however, because 50% of all relapses in the IT occurred later than 2 years after transplantation, the EFS declined to 55% (95% CI, 34% to 76%) at 42 (SD, 11) months. There were no late relapses in the observation group. EFS in the entire cohort was 58% (95% CI, 42% to 73%) at 42 (SD, 11) months after transplantation. Evidence of disease before transplantation remained a significant predictor of relapse, whereas development of chronic GVHD was protective against relapse. Ó
INTRODUCTION
Relapse of leukemia after hematopoietic stem cell transplantation (HSCT) remains the most common cause of transplantation failure, and few options are available for its treatment. Data from the Center for International Blood and Marrow Transplant Research indicate that the incidence of relapse after transplantatiom is 30% to 35% for children with acute lymphoblastic leukemia (ALL) [1] and 39% for children undergoing transplantation for acute myelogenous leukemia (AML) [2] . In the 1990s, with development of more sensitive chimerism testing, the presence of residual host cells after HSCT for leukemia was recognized as an important predictor of relapse. Bader et al. [3] and Barrios et al. [4] showed that the presence of an increasing amount of host cells after HSCT for leukemia was associated with an approximately 90% chance of relapse in children and adults. To reduce this high relapse rate, European investigators used pre-emptive immunotherapy (IT) consisting of fast withdrawal of immunosuppression (FWI) and donor lymphocyte infusions (DLI) in pediatric patients with documented increasing host chimerism or persistent mixed chimerism (MC) [5] [6] [7] .
In 2005, we started using chimerism-based post-transplantation IT. The results of our first multi-institutional prospective feasibility study were published previously [8] .
In that study, we validated the use of subset chimerism testing and confirmed the relationship between MC and relapse. Patients with MC in any of peripheral blood (PB) subsets who did not receive intervention had a 71% relapse rate as opposed to an 11% relapse rate in patients with full donor chimerism (FDC) [8] .
This second prospective multi-institutional study was designed to prospectively evaluate efficacy and toxicity of pre-emptive chimerism-based IT in pediatric hematologic malignancies. We describe chimerism data, details of immunomodulatory interventions, the incidence of graftversus-host disease (GVHD), the relapse rate, and risk factors for relapse.
PATIENTS AND METHODS
Patients between 6 months and 25 years of age receiving a myeloablative HSCT for acute leukemia (AML, ALL, biphenotypic leukemia), juvenile myelomonocytic leukemia, or myelodysplastic syndromes were eligible for this study. Donors and recipients were required to be HLA matched at a minimum of 7 of 8 loci (A, B, C, DRB1), using high-resolution typing. Only patients receiving unmodified bone marrow (BM) or PB as a stem cell source were included, and there was a requirement that donor cells be available for additional DLIs. All patients and all donors provided written informed consent. Patients were enrolled at Benioff Children's Hospital at University of California San Francisco and All Children's Hospital, St. Petersburg, Florida from 2009 until 2012. The study was approved by the committees on human research from both institutions as well as the National Marrow Donor Program, and was registered with ClinicalTrials.gov as NCT01036009.
Definitions
MC was defined as the presence of 1% or more of host cells in any of the tested subsets. To initiate FWI, MC was required on 2 different tests: either PB and BM performed at the same time, or 2 PB or 2 BM specimens performed 2 weeks apart. FDC was defined as 100% donor in all tested subsets.
Assignment to Treatment Arms and Schedule of Chimerism Testing
From November 2009 until November 2010, the study required that the first chimerism test be done on day 30 AE 7 after transplantation and confirmatory chimerism test be done on day 45 AE 7, at which time PB and BM chimerism tests were obtained. The assignment to the intervention arm was done after MC was confirmed on 2 subsequent tests done 2 weeks apart. The intervention consisting of fast withdrawal of calcineurin inhibitor (CNI) started on day 60 AE 7. The CNI was tapered over 3 AE 1 weeks. However, because of a number of early relapses that occurred before the patient could be randomized to the intervention arm, in November 2010 the study was amended to obtain chimerism from both PB and BM on day 28 AE 7. Confirmatory chimerism was done only if there was a discrepancy between PB and BM chimerism (eg, if PB showed 100% donor in all subsets and BM 1 Peripheral blood 2 Bone marrow 3 Minimal residual disease 4 Intervention will involve fast withdrawal of immunosuppression and DLI until full donor chimerism is achieved. 5 showed MC in any of the subsets, BM would be repeated 2 weeks later, and if MC persisted, the intervention would start). Intervention with FWI started earlier in the amended study, on day 45 AE 7, as opposed to day 60 AE 7. Patients who had 100% donor chimerism on all PB and BM subsets, patients with any evidence of acute GVHD or peri-engraftment syndrome (defined as fever, rash AE respiratory symptoms occurring within 96 hour of engraftment and resolving with a short course of steroids), and those who had >1% leukemic blasts on the first post-transplantation disease evaluation test, were assigned to the observation arm. A subgroup of patients treated before November 2010 who had an event (death or relapse) before randomization occurred are presented separately as an "early event" group. Figure 1 depicts the study intervention algorithm, as used since November 2010. PB chimerism testing included whole blood and CD3 þ lineage in all patients and included the leukemia-specific subset defined as CD19
þ lineage in patients with B lymphoid malignancies and CD14/15 þ lineage in patients with myeloid malignancies. Bone marrow evaluation for chimerism and disease evaluation were required for all patients who did not have evidence of acute GVHD, and was done at days 28 to 45 after transplantation. Disease evaluation included morphology and either multiparametric flow, PCR, or cytogenetics by FISH analysis, depending on which test was used for disease evaluation before transplantation. Chimerism testing was done on whole BM, and whenever a sufficient specimen was available, subsets were also tested (CD34 þ and CD3 þ in all patients and leukemia-specific subsets, defined as CD33 þ and CD14/15 þ in patients with myeloid malignancies and CD19 þ in those with lymphoid malignancies). Details of isolation of cell subsets and chimerism testing using a semi-quantitative PCR-based method involving amplification of genes containing short tandem repeats were previously published [8] . As previously described, the sensitivity of the chimerism assay was dependent on the percentage of donor cells present. If the donor cells were 95% to 99%, the assay sensitivity was 1%; for 90% to 94% donor cells, the sensitivity was 3%; for 11% to 89% donor cells, the sensitivity of the assay was 6% [8] .
Schedule and Dose of Donor Lymphocyte Infusions
Patients were eligible for IT with DLIs if MC persisted after FWI. Four weeks after each DLI dose, the chimerism test was repeated and if MC was documented, the patient underwent a subsequent, larger dose of DLI. DLI was repeated every 6 to 8 weeks until FDC in all PB subsets was documented on 2 tests that were done 4 weeks apart. Once FDC was achieved, chimerism was tested annually or sooner if clinically indicated.
Recommended DLI doses and schedule of DLI escalation were as follows: for mismatched related and unrelated donor transplant recipients, the first DLI dose was 1 Â 10 5 The study was designed to discontinue all interventions 1 year after transplantation; however, if FDC was not achieved by 1 year after transplantation, patients could have continued DLIs off study. The study did not require confirmation of FDC in the BM at the end of intervention, except in instances where the initial testing showed MC in BM alone, which did not occur in any patients. If at any point during the intervention a patient developed GVHD, IT was discontinued and treatment of GVHD was initiated.
Acute and chronic GVHD were graded using published criteria [9, 10] . Supportive care, conditioning regimens, and GVHD prophylaxis were provided as per standard of care. All patients received CNI and an additional agent (methotrexate or mycophenolate mofetil) for GVHD prophylaxis, and some patients received pre-HSCT serotherapy.
Statistical Analysis
Data were analyzed using SPSS v16.0 statistical program (SPSS Inc. Chicago, IL). Descriptive statistics, including the Fisher's exact test with 2-sided P values for the comparison of categorical variables and 2-sided Student's t-test for comparison of means, were used. Event-free survival (EFS) was calculated using Kaplan-Meier analysis from the time of transplantation until the last contact for living patients or date of event (relapse or toxic death). The mean survival and 95% confidence interval (CI) are presented. Log-rank test was used for comparison of distribution curves. Table 1 outlines characteristics of 43 patients treated in this study, including conditioning regimens, GVHD prophylaxis, disease status before transplantation, donor types, and stem cell sources. Mean age at the time of transplantation was 10.8 (SD, 6.5) years (range, 1 to 24 years). Nineteen patients (44%) had pretransplantation disease evaluation done by multiparametric flow performed at the University of Washington, Seattle; the remaining patients had pretransplantation disease evaluation done by morphology, immunoflow, and/or cytogenetics and FISH testing at a local institution. Post-Transplantation Chimerism Testing, Disease Evaluation, and Assignment to Treatment Arms Early post-transplantation chimerism tests, used for decision-making for assignment to the intervention arm, were obtained from PB on post-transplantation day 32.5 (SD, 8.8) and BM on day 37.9 (SD, 9.9). Table 2 summarizes results of early post-transplantation chimerism tests and shows overall very high levels of donor chimerism.
RESULTS

Patient and Transplantation Characteristics
Patients with Early Post-Transplantation Events
Five patients could not be assigned to either observation or intervention arm because of early events. One patient who had treatment-related AML (-7q) did not engraft and had evidence of AML progression on the first posttransplantation BM exam. Three patients who were engrafted with donors' cells had >1% leukemic blasts by multiparametric flow on the first post-transplantation BM evaluation and were not eligible for pre-emptive IT. One patient died 2 months after transplantation, without evidence of disease, because of liver dysfunction. No patients in this group achieved FDC. After the protocol was modified and confirmatory testing at day þ45 was eliminated, no additional events before randomization were encountered.
Observation Arm Outcomes
Twelve patients (28%) were assigned to the observation arm: 7 (58%) because of the presence of acute GVHD, 2 (17%) because of peri-engraftment syndrome, and 3 (25%) because of FDC in all tested subsets and no evidence of GVHD. Only 4 of 9 (44%) patients who had GVHD or peri-engraftment syndrome had FDC in all tested subsets on the early posttransplantation testing. All surviving patients in the observation group achieved FDC in PB in all subsets at a median of 48 days after transplantation (range, 21 to 355). Two patients in the observation group died because of relapse, which occurred at 4 months after transplantation in both patients. One of them had evidence of grade 2 acute GVHD and MC; the other patient, for whom this was a second transplantation for monosomy 7, had no GVHD and had FDC on the initial post-transplantation test (although BM subsets could not be tested). Grade II to IV acute GVHD was present in 7 of 12 patients (58%); however, only 3 of 12 (25%) patients had GVHD of grade III or higher. Chronic extensive GVHD was present in 6 of 12 (50%) patients in this group, and 3 of them are still on therapy at 45, 46, and 60 months after transplantation. Table 3 summarizes relapse rate, GVHD rates, 2-year EFS, and EFS at the mean study follow-up (42 months) by treatment arm and by chimerism status. Table 4 presents the details of intervention including time to FWI, time and number of DLIs, chimerism, GVHD, and outcomes. Twenty-six patients (60%) underwent FWI and 14 (33%) underwent subsequent DLIs. Median time to initiation of FWI was day 49 (range, 35 to 85), and median time to discontinuation of CNI was day 75 (range, 49 to 113). After FWI, 3 of 26 (11.5%) patients developed acute GVHD of grades I, II, and IV. The patient with grade IV GVHD (patient 25UC) progressed to severe chronic lung GVHD and died from fungal infection 7 months after transplantation.
Intervention ArmdFWI and DLI
The median time to first DLI was 118 days (range, 85 to 194) and the median time to the last DLI was 223 days (range, 85 to 627). Three patients received 1 DLI only, 3 received 2 DLIs, 4 received 4 DLIs, and 1 patient each received 5, 6, 7, and 8 DLIs. Cumulative DLI dose in millions of CD3 þ cells/kg of recipient's weight is presented in Table 4 and ranged between . aGVHD indicates acute graft-versus-host-disease; cGVHD, chronic graft-versus-host-disease; n/a, not available; f/u, follow-up. Data presented are n (%) unless otherwise indicated. 
Chimerism after intervention
Three patients in the intervention arm required continuation of DLIs past 1 year after transplantation; 2 of them achieved FDC at 467 and 977 days after transplantation. One patient (05UC) did not achieve FDC despite 8 DLIs and sustained late relapse. All surviving patients in the intervention arm (16 of 26) have achieved FDC in all subsets. One patient with T cell ALL (39UC) developed 1% host cells in CD3 þ lineage at 16 months after transplantation after having previously achieved FDC. She has not received additional DLIs because of a history of autoimmune hemolytic anemia requiring steroids. Her MRD is followed by high throughput sequencing and has remained negative.
Outcomes for the Entire Cohort
The mean follow-up of living patients is 42 (SD,10) months with a range of 28 to 60 months. The Kaplan-Meier estimate of EFS in all 43 patients enrolled in this study was 58% (95% CI, 42% to 74%), with 14 of 43 (33%) patients sustaining relapse, 2 (4.6%) dying from toxic death, and 1 (2.3%) developing a secondary myelodysplastic syndrome, after transplantation for ALL. Figures 2 and 3 depict EFS and relapse rates based on early post-transplantation chimerism and intent to treat (intervention arm þ early events versus observation arm). After intervention, patients with MC did not have significantly different EFS or relapse rates compared with those who achieved FDC spontaneously (log rank P for EFS, .06; for relapse rate, P ¼ .12). Late relapses were seen only in the intervention arm. There were no differences in EFS between lymphoid and myeloid malignancies (log-rank P ¼ .68). Figure 4 depicts EFS by pretransplantation disease status. Overall, 7 of 11 (63%) patients with positive disease before transplantation relapsed compared with 7 of 32 (22%) patients with negative pretransplantation disease (2-sided Fisher exact, P ¼ .02). In the intervention arm, 4 of 5 (80%) patients with positive disease before transplantation relapsed, compared with 4 of 21 (19%) patients without pretransplantation evidence of disease (2-sided Fisher exact, P ¼ .02).
Predictors of Relapse
None of the 9 patients with chronic GVHD relapsed, compared with 14 of 34 (42%) patients without chronic GVHD (2-tailed Fisher's exact P ¼ .02). Three of 11 (27%) patients with acute GVHD (all of whom had GVHD grade II or less) relapsed, compared with 11 of 32 (34%) patients without acute GVHD (P ¼ .48). Twenty-nine patients who underwent transplantation after the intervention was moved to an earlier time-point had mean EFS of 66% as opposed to an EFS of 50% in the 14 patients receiving intervention later after transplantation. This was not significantly different (log rank P ¼ .53).
Early post-transplantation chimerism as a predictor of relapse Table 5 describes relapse rates and early posttransplantation BM and PB chimerism results. As seen in the table, in patients treated with pre-emptive IT approach, only MC in BM leukemia-specific lineage remained predictive of relapse.
DISCUSSION
Our prospective study of chimerism-based IT indicates that FWI and DLI resulted in acceptable toxicities (GVHD developed in 19% of patients and toxic death due to GVHD in 4%). The use of IT allowed patients in the intervention group to achieve EFS rates similar to those achieved by patients with early acute GVHD and/or full donor chimerism. However, relapses occurring later than 2 years after transplantation were seen only in the intervention arm, suggesting that the alloreactive effect of IT was waning over time. Patients with evidence of disease before transplantation remained at an increased risk of relapse, despite the intervention. As expected, chronic GVHD was protective against relapse. The relapse rate in our entire cohort remained high (33%), likely due to underestimated disease burden, as only 44% of patients had pretransplantation disease evaluation done by multiparametric flow and to inclusion of high-risk patients, such as those undergoing second transplantation or having treatment-related AML.
Detection of MC is not equivalent to detection of residual disease, as early post-transplantation MC is caused predominantly by normal recipient hematopoietic cells [11] . Persistence of host cells may reduce the clinical graft-versusleukemia effect by inducing tolerance [11] . In animal studies, host antigen-presenting cells in mixed chimeras allow for improved presentation of host antigens to donor lymphocytes, leading to superior alloreactivation of the intolerant donor lymphocytes [12] .
Early studies showed that children with AML (n ¼ 15) and ALL (n ¼ 31) who received pre-emptive IT for increasing host chimerism after HSCT had 36% and 37% long-term survival, respectively, whereas there were no survivors among children with increasing host chimerism who did not receive pre-emptive IT [5, 6] . The three-year EFS rate for the entire cohort of children included in pre-emptive IT approach between 1996 and 2001 was 52% for AML [5] , and 54% for ALL [6] , respectively. In a subsequent study conducted between 2005 and 2009, Rettinger et al. started intervention based on presence of MC rather than increasing host chimerism [7] and EFS increased to 46% in the IT group, compared with 36% in the previous study [6, 7] . EFS for the entire cohort of patients also improved to 66% (95% CI, 53% to 76%) from 52% in the previous study [6, 7] .
In 2005, we conducted the first United States pediatric multi-institutional feasibility study of chimerism-based IT and indicated that MC should be used as the basis for Bold indicates statistical significance.
* Includes number of patients tested for the specific subset. post-transplantation IT, as waiting for documentation of increasing host chimerism delayed intervention and resulted in increased risk of relapse [8] . The study also described the importance of achieving FDC in all PB cell lineages, as patients with FDC in all subsets had an 11% relapse rate compared with a 71% relapse rate in patients with MC in any of the PB subsets who did not undergo intervention [8] .
When compared to historic control from our feasibility study, which had the same inclusion criteria, the relapse rate in patients with MC who were eligible for intervention declined from 71% to 39% (2-tailed Fisher's exact, P ¼ .20).
There are a number of differences between the European approach to chimerism-based IT, most recently published in Rettinger's study, and our approach [7] . We tested chimerism less frequently and did not include patients who received T celledepleted grafts. We used gradual (over 3 to 4 weeks) withdrawal of CNI as opposed to abruptly stopping CNI. We used subset chimerism testing of PB and continued intervention until 100% rather than !99% donor chimerism was confirmed in all subsets. Finally, we excluded from IT patients with any acute GVHD grade or peri-engraftment syndrome. Based on our definition of mixed chimerism, a higher number of patients were eligible for IT and a larger proportion of patients received pre-emptive IT than in the European study (60% versus 18%) [7] . It is likely that some of the patients who underwent IT in our study would have spontaneously achieved FDC if we had waited longer. However, the toxicities of our treatment were acceptable, and prevention of relapse was a priority as there were no longterm survivors among patients who relapsed in our study. Twelve percent of patients relapsed or had an event before randomization occurred. Other studies using the preemptive IT approach describe that 7% to 15% of patients eligible for pre-emptive IT did not receive it for various reasons, and all ultimately relapsed and died [5] [6] [7] . Earlier start of IT (before day 45), as done in our study since November 2010, reduced the number of children who are ineligible for IT because of early events.
The IT did not reduce the risk of relapse in a group of patients with pretransplantation disease, 63% of whom relapsed. A recent Children's Oncology Group study of pediatric ALL indicated a 60% relapse rate in children who were documented to have !.1% leukemia cells before transplantation and who did not receive any post-transplantation pre-emptive therapy [13] . Balduzzi et al. reported a 62% relapse rate in children with ALL with documented pretransplantation MRD of !10 À4 [14] . In that study, patients with positive MRD before transplantation were eligible for FWI but not DLI. DLIs were given to 7 patients with posttransplantation evidence of MRD or increasing host chimerism. The DLI dose was 1 Â 10 6 /kg in matched related transplantations and 5 Â 10 5 /kg in matched unrelated donor transplantations. Only 1 of 7 (14%) patients is a long-term survivor [14] . Lankester et al. pioneered preemptive FWI and DLI in 18 children with ALL, based on pretransplantation MRD detected by PCR at a level of !1 Â 10 À4 [15] . Unfortunately, the relapse rate in this high-MRD group was 70%, despite pre-emptive IT. The starting DLI dose in that study was 1 Â 10 6 /kg for matched related and unrelated T cellereplete transplantations [15] . However, a few recent reports indicate that higher DLI doses than those used by European investigators and in our study may be able to overcome post-transplantation MRD. Investigators from China recently described the efficacy of a pre-emptive IT approach after documenting MRD after transplantation [16, 17] . Yan et al. used DLI concomitantly with chemotherapy and gave 1 to 2 log higher doses than were used in our study [17] . Long-term survival of 56 patients with post-transplantationepositive MRD was w40% in that study [17] . Rujkiyanont et al. used 1 log higher DLI doses than described in our study. In 3 of 7 (43%) children, the BM MRD, which was positive after transplantation by multiparameter flow cytometry, reverted to negative and remained negative [18] . It is possible that higher DLI doses given for MRD may achieve better leukemia control; however, the long-term outcomes of pre-emptive IT in patients with small amounts of disease require further study.
Finally, we encountered a number of late relapses in patients receiving immunologic intervention who did not develop chronic GVHD, which indicates a reduction in alloreactive responses over time. None of the patients with chronic GVHD sustained a relapse. Late relapses in patients receiving IT have been previously described only by Lankester et al. [15] . In his study of pre-emptive IT given to patients with positive MRD before transplantation, 27% of relapses occurred later than 1 year after transplantation and 20% of relapses occurred more than 2 years after transplantation [16] . Our patients had a lower GVHD rate than typically described in studies of pre-emptive IT, some of which report GVHD incidence as high as 70% [19] . Although chronic GVHD is protective against relapse, our goal was to avoid it, given associated morbidities. Since identifying the risk of late relapse, we have changed our practice and are following patients with FDC but without chronic GVHD for a minimum of 3 years after transplantation. We are now confirming FDC in BM, in particular in CD34 þ and leukemiaspecific lineage, and evaluating MRD by the most sensitive available technique at the end of pre-emptive IT intervention [20, 21] . Readily available strategies to enhance IT and prevent relapse without increasing the risk of GVHD include concomitant use of DLI with immunosuppression or with immunomodulatory agents, such as azacitidine [22] [23] [24] [25] [26] . Also, a number of new immunologically based approaches for reduction of pre-or post-transplantation MRD, such as chimeric antigen receptor T cells, bispecific T cell engagers, and advanced conjugated immunotoxins (eg, moxetumomab) are being actively studied [27, 28] . Since the initiation of our study, more sensitive techniques, such as immunoglobulin and T cell receptor gene high-throughput sequencing, have been introduced for the follow-up of pre-and post-transplantation MRD for patients with ALL [29, 30] . Additional studies are still required to better define the MRD cut-offs and establish positive and negative predictive values for different testing time points. Recent comparison between chimerism testing and qPCR detection of MRD after transplantation indicated that clone-specific quantitative polymerase chain reaction (qPCR) was significantly more specific and sensitive in predicting relapse than the finding of increasing host chimerism [31] . The MRD relapse was detected by qPCR an average of 173 days before detection of hematologic relapse [31] .
CONCLUSION
Our prospective study of chimerism-based IT indicates that FWI and DLI resulted in acceptable toxicities (GVHD developed in 19% of patients and toxic death due to GVHD in 4%). The use of IT allowed patients with early posttransplantation MC to achieve similar survival rates as patients who achieved FDC spontaneously. Relapses occurring later than 2 years after transplantation were seen only in patients receiving post-transplantation IT, suggesting that the alloreactive effect of adoptive IT wanes over time. Patients with evidence of disease before transplantation remained at an increased risk of relapse despite IT. These patients likely require more potent IT to overcome larger disease burden or better methods of reducing disease burden before HSCT. Despite IT, early BM mixed chimerism in leukemia-specific lineage remained predictive of relapse. Going forward, chimerism will likely not be used as the sole basis for prediction of relapse as it is less sensitive and specific than PCR-based MRD tests; however, it may still be useful as a marker of tolerance and potential for a potent alloreactive response. This study provided valuable data regarding the optimal timing and speed of FWI, timing and dose of DLIs, and duration of follow-up after IT. These data should be applicable to future studies of post-transplantation IT regardless of what testing method is used to detect MRD or the type of immunotherapy.
